WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Museums in N China's Tianjin offer night tours, attract visitors with immersive eventsCraft Project fair held in old Damascus, SyriaInPics: People celebrate Laba Festival in BeijingChina's Jiangsu Acrobatic Troupe performs in Stuttgart of Germany6 Jordanian students win Chinese ambassador's scholarshipFrank Nazar scores on first shot in NHL debut with Chicago BlackhawksChina to launch national survey on cultural relics81st World Science Fiction Convention kicks off in ChengduResearch Center for Archaeology of Yan Culture founded in BeijingShanghai sculpture show sees Rodin, Sanxingdui in dialogue
3.7107s , 5260.3671875 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,World Winds news portal